Exquisite antitumour response to trastuzumab in a patient with no evidence of Ras–Raf–MAPK and PI3K–Akt pathways activation

M.S Mano,A Awada,A Minisini,V Durbecq,A Di Leo,M Piccart

doi:10.1016/j.breast.2003.11.009

Exquisite antitumour response to trastuzumab in a patient with no evidence of Ras–Raf–MAPK and PI3K–Akt pathways activation

M.S Mano, A Awada + Show 4 more

Open Access

https://doi.org/10.1016/j.breast.2003.11.009

Copy DOI

Journal: The Breast	Publication Date: May 6, 2004
Citations: 4	License type: cc-by-nc-nd

Affiliation: Institut Jules Bordet

#HER2-targeted Monoclonal Antibody #Diagnosis Of Metastatic Breast Cancer + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

We report on the case of a patient with a diagnosis of a HER2-overexpressing metastatic breast cancer which was refractory to a combination of a Raf kinase inhibitor and docetaxel, but highly sensitive to trastuzumab, a HER2-targeted monoclonal antibody. Interestingly, there was no evidence of Ras–Raf–MAPK or PI3K–Akt pathways activation.

Full Text